Leaflet NERLYNX 40mg film-coated tablets
Indicated for: breast cancer
Route of administration: oral
Substance: neratinib (tyrosine kinase inhibitor)
ATC: L01EH02 (Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors)
This medicine may affect fertility.
Handle with special care.
Effective contraception is required during treatment.
Do not use this medicine while breastfeeding.
Do not use this medicine during pregnancy.
Avoid grapefruit and grapefruit juice.
This medicine may affect the liver.
This medicine may have important interactions with other medicines.
This medicine may lower blood cell counts.
This medicine is subject to additional monitoring.
Periodic laboratory tests may be required during treatment.
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
This medicine may increase the risk of heart rhythm disturbances.
Neratinib is an oral anti-cancer medicine used in certain adults with early-stage HER2-positive, hormone receptor-positive breast cancer after treatment with trastuzumab. Its aim is to lower the risk of the cancer coming back. In some countries it may also be used for advanced disease in combinations chosen by an oncology specialist.
It works by blocking growth signals inside cancer cells. Neratinib is usually taken once daily with food for the period prescribed by your doctor, and tablets should be swallowed whole. Follow the schedule exactly, including any anti-diarrhoea prevention medicine you are given. Grapefruit and some acid-reducing medicines can interact with neratinib.
The most important side effect is diarrhoea, which can be severe and may cause dehydration. Other possible effects include nausea, vomiting, abdominal pain, tiredness, reduced appetite, rash, mouth sores and changes in liver blood tests. Contact your care team quickly if diarrhoea continues, or if you feel dizzy, weak or unable to drink enough fluids.
Blood tests, especially liver tests, are needed before and during treatment. Neratinib can harm an unborn baby, so effective contraception is required and pregnancy must be reported immediately. Do not breastfeed during treatment unless your doctor says it is safe. Fever, jaundice, severe abdominal pain or signs of dehydration need urgent assessment.
General data about NERLYNX 40mg
- Substance: neratinib
- Date of latest medicines list: 01-06-2026
- Product code: W71654001
- Concentration: 40mg
- Pharmaceutical form: film-coated tablets
- Quantity: 180
- Product type: Generic medicine
- Price: 19507.58 RON
- Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.